کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2794441 | 1155284 | 2012 | 4 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia](/preview/png/2794441.png)
Imatinib (IM) is the current first line treatment for chronic myeloid leukemia (CML). However, the disease will progress in the majority of patients pausing IM. IFN-α may intensify the response and increase the percentage of patients maintaining remission after IM cessation. Eleven patients with stable (⩾2 years) complete cytogenetic responses (CCyR) on IM therapy were recruited to the study. They were administered Peg-IFN-α for 9 months before and for 3 months following IM discontinuation. During the 12 months of Peg-IFN-α therapy the remission status improved in five (45%) of the patients. Six (55%) of the patients experienced cytogenetic relapses at a median period of 8 months (range 2–33) after IM withdrawal. All six patients regained CCyR following IM restart. With a median follow up of 47 months (range 35–50), five (45%) out of the 11 studied patients maintain cytogenetic response off IM therapy. The role of Peg-IFN-α in patients pausing IM is to be further evaluated. This study is registered with ClinicalTrials.gov, number NCT00297570.
► IFN-α may intensify the response of CML pts after Imatinib (IM) cessation.
► We administered Peg-IFN-α for 9 months before and for 3 months following IM discontinuation to 11 CML pts.
► With a median follow up of 47 months (range 35–50), 5 (45%) out of the 11 pts maintain cytogenetic response off IM therapy.
Journal: Cytokine - Volume 57, Issue 2, February 2012, Pages 290–293